一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts.
Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤免疫中功能空间的一个关键未知点是CD4 T细胞是否依赖于瘤内MHCII肿瘤抗原识别。在乳腺和胰腺肿瘤中已发现表达MHCII的抗原呈递癌相关成纤维细胞(apCAFs),并被认为具有免疫抑制作用。本分析显示,抗原呈递成纤维细胞在人类肺非小细胞癌中频繁出现,在那里它们似乎积极促进而非抑制MHCII免疫。肺apCAFs直接激活效应CD4 T细胞的TCR,同时产生C1q,后者作用于T细胞C1qbp以使其免于凋亡。成纤维细胞特异性MHCII或C1q缺失损害了CD4 T细胞免疫并加速了肿瘤生长,而在过继转移的CD4 T细胞中诱导C1qbp则扩大了其数量并减少了肿瘤。总体而言,我们已在肺中表征了一个具有肿瘤抑制特性的抗原呈递成纤维细胞亚群,并提出癌症免疫疗法可能强烈依赖于原位MHCII抗原呈递。
A key unknown of the functional space in tumor immunity is whether CD4 T cells depend on intratumoral MHCII cancer antigen recognition. MHCII-expressing, antigen-presenting cancer-associated fibroblasts (apCAFs) have been found in breast and pancreatic tumors and are considered to be immunosuppressive. This analysis shows that antigen-presenting fibroblasts are frequent in human lung non-small cell carcinomas, where they seem to actively promote rather than suppress MHCII immunity.
Lung apCAFs directly activated the TCRs of effector CD4 T cells and at the same time produced C1q, which acted on T cell C1qbp to rescue them from apoptosis. Fibroblast-specific MHCII or C1q deletion impaired CD4 T cell immunity and accelerated tumor growth, while inducing C1qbp in adoptively transferred CD4 T cells expanded their numbers and reduced tumors.
Collectively, we have characterized in the lungs a subset of antigen-presenting fibroblasts with tumor-suppressive properties and propose that cancer immunotherapies might be strongly dependent on in situ MHCII antigen presentation.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。